Table 1.
Clinical-pathological features of PCa patients in early BCR and long-term BCR survival groups before and after PSM.
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
| Variable | early BCR | Long-term BCR survival | P | early BCR | Long-term BCR survival | P |
| age | 0.26 | 1.00 | ||||
| < 65 | 12(30.8) | 118(41.7) | 12(30.8) | 13(33.3) | ||
| ≥ 65 | 27(69.2) | 165(58.3) | 27(69.2) | 26(66.7) | ||
| Gleason score | <0.001 | 1.00 | ||||
| 6 | 1(2.6) | 36(12.7) | 1(2.6) | 1(2.6) | ||
| 7 | 11(28.2) | 154(54.4) | 11(28.2) | 10(25.6) | ||
| 8 | 10(25.6) | 34(12.0) | 10(25.6) | 10(25.6) | ||
| 9 | 17(43.6) | 56(19.8) | 17(43.6) | 18(46.2) | ||
| 10 | 0(0) | 3(1.1) | 0(0) | 0(0) | ||
| T stage | 0.01 | 0.58 | ||||
| Tx | 0(0) | 4(1.4) | 0(0) | 0(0) | ||
| T2 | 6(15.4) | 123(43.5) | 6(15.4) | 7(17.9) | ||
| T3 | 32(82.1) | 151(53.4) | 32(82.1) | 32(82.1) | ||
| T4 | 1(2.6) | 5(1.8) | 1(2.6) | 0(0) | ||
| N stage | 0.10 | 0.71 | ||||
| Nx | 3(7.7) | 44(15.5) | 3(7.7) | 4(10.3) | ||
| N0 | 25(64.1) | 194(68.6) | 25(64.1) | 27(69.2) | ||
| N1 | 11(28.2) | 45(15.9) | 11(28.2) | 8(20.5) | ||
PCa: prostate cancer
BCR: biochemical recurrence
PSM: propensity score matching